Metabolism and disposition kinetics of nicotine
J Hukkanen, P Jacob III, NL Benowitz - Pharmacological reviews, 2005 - Elsevier
Nicotine is of importance as the addictive chemical in tobacco, pharmacotherapy for
smoking cessation, a potential medication for several diseases, and a useful probe drug for …
smoking cessation, a potential medication for several diseases, and a useful probe drug for …
The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification
Human UDP-glucuronosyltransferase (UGT) exists as a superfamily of 22 proteins, which
are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of …
are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of …
[HTML][HTML] An ethnopharmacological review on the therapeutical properties of flavonoids and their mechanisms of actions: A comprehensive review based on up to date …
DH Abou Baker - Toxicology reports, 2022 - Elsevier
Flavonoids-a class of low molecular weight secondary metabolites-are ubiquitous and
cornucopia throughout the plant kingdom. Structurally, the main structure consists of C6-C3 …
cornucopia throughout the plant kingdom. Structurally, the main structure consists of C6-C3 …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
Molecular mechanism of phase I and phase II drug‐metabolizing enzymes: implications for detoxification
T Iyanagi - International review of cytology, 2007 - Elsevier
Enzymes that catalyze the biotransformation of drugs and xenobiotics are generally referred
to as drug‐metabolizing e nzymes (DMEs). DMEs can be classified into two main groups …
to as drug‐metabolizing e nzymes (DMEs). DMEs can be classified into two main groups …
Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated …
JY Han, HS Lim, ES Shin, YK Yoo, YH Park… - Journal of clinical …, 2006 - ascopubs.org
Purpose To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7,
and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment …
and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment …
[HTML][HTML] Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
M Panczyk - World Journal of Gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …
showing its high degree of inter-individual differentiation, as a result of large international …
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
LE Carlini, NJ Meropol, J Bever, ML Andria, T Hill… - Clinical Cancer …, 2005 - AACR
Purpose: Capecitabine and irinotecan are commonly used in the treatment of metastatic
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …
Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography–tandem mass …
Uridine-disphosphate glucuronosyl transferase (UGT) enzymes catalyze the formation of
glucuronide conjugates of phase II metabolism. Methods for absolute quantification of …
glucuronide conjugates of phase II metabolism. Methods for absolute quantification of …
Pharmacogenetics of irinotecan metabolism and transport: an update
NF Smith, WD Figg, A Sparreboom - Toxicology in vitro, 2006 - Elsevier
The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …